Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesQuality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTCâ??GELA H8 randomised controlled trial
The Lancet Oncology - Online First, 10/14/09
Heutte N et al. – HRQoL data after treatment for early-stage Hodgkin's lymphoma show that patients experience strain and limitations in all subdomains apart from cognitive functioning (QLQ-C30), and also have reduced motivation (MFI-20). Differences in HRQoL improvement with time were linked to age and sex, but not type of treatment. Fatigue status at the end of treatment seems to predict subsequent HRQoL.
Methods- Patients received HRQoL questionnaires at end of primary therapy and during follow-up
- EORTC QLQ-C30 used to assess HRQoL, and Multidimensional Fatigue Inventory (MFI-20) used to assess fatigue
- Changes of mean HRQoL scores over time analysed with mixed models
- Multiple polytomic nominal logistic regression done to identify independent baseline predictors of fatigue within MFI-20 dimensions
- 2666 assessments from 935 patients
- Mean follow-up 90 mos (range 52—118)
- Age affected all functioning and symptom scores except emotional functioning, with younger age associated with higher functioning and lower severity of symptoms; improvement with time showed similar patterns between age groups
- Women reported lower HRQoL and higher symptom scores than men
- 3·2% (14/439 for role functioning) to 9·7% (43/442 for social functioning) and 5·8% (29/498 for reduced motivation) to 9·9% (49/498 for general fatigue) of patients reported impairments of 10 points or more (on a 0—100 scale) in QLQ-C30 and MFI-20 scores, respectively, independent of age and sex
- Emotional domains more affected than physical ones
- No relation between HRQoL outcome and type of treatment
- Fatigue (MFI-20 scores) at end of treatment was only predictive variable for persistent fatigue, with odds ratios varying from 2·58 (95% CI 1·00—6·67) to 41·51 (12·02—143·33)
- Sensitivity analyses adjusting for missing data were much same as main results
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor